The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00666926




Registration number
NCT00666926
Ethics application status
Date submitted
26/03/2008
Date registered
25/04/2008
Date last updated
21/03/2013

Titles & IDs
Public title
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Scientific title
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies
Secondary ID [1] 0 0
A8031001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Head and Neck Neoplasm 0 0
Prostatic Neoplasm 0 0
Pancreatic Neoplasm 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate
Cancer 0 0 0 0
Head and neck
Cancer 0 0 0 0
Pancreatic

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PF00562271
Treatment: Drugs - PF00562271
Treatment: Drugs - PF00562271
Treatment: Drugs - PF00562271

Experimental: 1 -

Experimental: 2 -

Experimental: 3 -

Experimental: 4 -


Treatment: Drugs: PF00562271
125 mg twice daily [BID] with food, tablet

Treatment: Drugs: PF00562271
125 mg BID with food, tablet

Treatment: Drugs: PF00562271
125 mg BID with food, tablet

Treatment: Drugs: PF00562271
125 mg BID with food, tablet

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) - At least possibly attributable to study treatment (Tx): Grade (Gr) 4 neutropenia (absolute neutrophil count [ANC] <500 cells/mm^3) for >7 days or Gr 3 febrile neutropenia (ANC <1000/mm^3, fever =38 degrees Celsius; Gr 4 thrombocytopenia (platelets <25,000 cells/mm^3); Gr =3 non-hematologic toxicity despite adequate medical intervention; Gr =3 confirmed prolonged QTc interval (>500 milliseconds [msec]); confirmed cardiac troponin I =99 percentile of reference range; Tx related toxicities with failure to receive =18 days Tx in 21-day cycle or inability to resume current dose level =14 days.
Timepoint [1] 0 0
Baseline up to Cycle 1 Day 21 (C1.D21)
Primary outcome [2] 0 0
Percentage of Participants With Tumor Metabolic Response (Reduction of =15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET) - Metabolic response demonstrated in any tumor reduction of =15% in tumor FDG standardized uptake value (SUV) in Cycle 1; based on the recommendations of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Participant must have had a baseline PET with at least 1 tumor lesion demonstrating an FDG SUV of =5.
Timepoint [2] 0 0
Baseline, C1.D14
Secondary outcome [1] 0 0
Maximum Serum Concentration (Cmax): PF-00562271 C0.D1, C1.D1
Timepoint [1] 0 0
Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 morning (am) dose
Secondary outcome [2] 0 0
Maximum Serum Concentration (Cmax): PF-00562271 C1.D14
Timepoint [2] 0 0
Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose
Secondary outcome [3] 0 0
Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C0.D1, C1.D1
Timepoint [3] 0 0
Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose
Secondary outcome [4] 0 0
Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C1.D14
Timepoint [4] 0 0
Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose
Secondary outcome [5] 0 0
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): PF-00562271 C0.D1, C1.D1 - Area under the serum concentration time-curve from zero to the last measured concentration; nanograms multiplied by hours per milliliters (ng*hr/mL).
Timepoint [5] 0 0
Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose
Secondary outcome [6] 0 0
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): PF-00562271 C0.D1, C1.D1 - AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).
Timepoint [6] 0 0
Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose
Secondary outcome [7] 0 0
Serum Decay Half-life (t 1/2): PF-00562271 C0.D1, C1.D1 - Serum decay half-life is the time measured for the serum concentration to decrease by one half.
Timepoint [7] 0 0
Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose
Secondary outcome [8] 0 0
Apparent Oral Clearance (CL/F): PF-00562271 C0. D1, C1.D1 - Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Timepoint [8] 0 0
Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose
Secondary outcome [9] 0 0
Minimum Observed Serum Trough Concentration (Cmin): PF-00562271 C1.D14
Timepoint [9] 0 0
Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose
Secondary outcome [10] 0 0
Area Under the Curve From Time Zero to the End of the Dosing Interval (AUCtau): PF-00562271 C1.D14
Timepoint [10] 0 0
Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose
Secondary outcome [11] 0 0
Observed Accumulation Ratio (Rac): PF-00562271 C1.D14 - Rac was the ratio of the Day 14 AUC0-tau (0 hour to last dose interval) and AUC during the corresponding time period after the lead-in dose (AUCtau C1.D14/AUCtau C0.D1).
Timepoint [11] 0 0
Escalation (Esc) cohort: C0.D1: 0 hr, and 0.5, 1, 2, 4, 6, 7,12 hrs post dose; Expansion (Exp) cohort: C0:D1: 0 hr, and 1, 2, 4, 8 hrs post dose; Esc and Exp cohorts: C1.D14 0 hour, and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose
Secondary outcome [12] 0 0
Maximum Serum Concentration (Cmax): MDZ
Timepoint [12] 0 0
C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose
Secondary outcome [13] 0 0
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): MDZ - Area under the serum concentration time-curve from zero to the last measured concentration.
Timepoint [13] 0 0
C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose
Secondary outcome [14] 0 0
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): MDZ - AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).
Timepoint [14] 0 0
C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose
Secondary outcome [15] 0 0
Time to Reach Maximum Observed Serum Concentration (Tmax): MDZ
Timepoint [15] 0 0
C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose
Secondary outcome [16] 0 0
Serum Decay Half-life (t 1/2): MDZ - Serum decay half-life is the time measured for the serum concentration to decrease by one half.
Timepoint [16] 0 0
C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose
Secondary outcome [17] 0 0
Apparent Oral Clearance (CL/F): MDZ - Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Timepoint [17] 0 0
C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose
Secondary outcome [18] 0 0
Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST) - Best response recorded from start of treatment (Tx) until disease progression. Complete response: disappearance of all target lesions. Partial response: =30% decrease in sum of longest dimensions (LD) of target lesions referencing baseline sum LD. Progressive disease: =20% increase in sum LD of target lesions from smallest sum LD recorded since Tx start or appearance of =1 new lesions. Stable disease: neither sufficient shrinkage to=PR nor sufficient increase to=PD during first 6 weeks after Tx start referencing smallest sum LD since Tx start.
Timepoint [18] 0 0
Baseline up to 12 cycles (cycle=21days)
Secondary outcome [19] 0 0
Phosphorylated Focal Adhesion Kinase (pFAK) - Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; FAK is overexpressed in a variety of human cancers. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Timepoint [19] 0 0
Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)
Secondary outcome [20] 0 0
Phosphorylated Mitogen Activated Pathway Kinase (pMAPK) - Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; MAPK regulates activities of several transcription factors. A defect in MAPK pathway leads to uncontrolled cell growth. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Timepoint [20] 0 0
Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)
Secondary outcome [21] 0 0
Phospho-SRC (pSRC) - Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; SRC proto-oncogenes are regulators of growth and differentiation of eukaryotic cells and are implicated in development of human tumors. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose; on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Timepoint [21] 0 0
Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)
Secondary outcome [22] 0 0
Caspase-3 - Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Timepoint [22] 0 0
Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)

Eligibility
Key inclusion criteria
- Pancreatic, head and neck, and prostatic neoplasms, and patients with non-hematologic
malignancies who have tumor appropriate for serial biopsy.

- Adequate organ function, including bilirubin less than 1.5 x ULN, and [Eastern
Cooperative Oncology Group] ECOG performance status of 0-2.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Clinically significant gastrointestinal abnormalities, requirement for systemic
anticoagulants or potent CYP 3A4 inhibitors, and history of clinically significant
cardiac or pulmonary disorders.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Pfizer Investigational Site - East Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Tennessee
Country [3] 0 0
Canada
State/province [3] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Verastem, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase
(FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography [PET]
scans due to advanced non-hematologic malignancies, including pancreatic, head and neck, and
prostatic neoplasms, and patients with other malignancies appropriate for serial biopsy.
Screening consists of a Fluorodeoxyglucose Positron Emission Tomography [FDG-PET] and tumor
imaging, medical history, physical examination, Eastern Cooperative Oncology Group [ECOG]
performance status, blood draws, a pregnancy test for female patients of childbearing
potential. Treatment consists of PF00562271 tablets continued until progression of disease,
unacceptable toxicity, or patient request. Evaluations for bioactivity are measured by serial
FDG-PET and blood tests for biomarkers related to FAK and PYK2 kinase activities.
Trial website
https://clinicaltrials.gov/show/NCT00666926
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications